Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07269808 · ClinicalTrials.gov registry record · Phase 3

Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration

A Phase 3 study of Anesthesia and Sedation, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 3
Development phase
100
Enrollment target
1
Study location

NCT07269808 is a Phase 3 study of Anesthesia and Sedation that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 109,408-participant average among 57 other Anesthesia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07269808, a Phase 3 study of Anesthesia and Sedation, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 3
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This study is a pragmatic, randomized controlled pilot trial comparing remimazolam with propofol for endoscopic procedures, designed to assess the feasibility and clinical outcomes associated with implementing a pragmatic randomized trial of sedation practices in the endoscopy setting.

Interventions

  • DRUG Remimazolam
  • DRUG Propofol

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2026-03-03
Est. Completion 2026-06-01
Phase Phase 3

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT07269808

The ClinicalTrials.gov registry entry for NCT07269808 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109,408-participant average among 57 other Anesthesia trials with a reported enrollment target (100% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Anesthesia appearing as the primary indexed condition, and to 2 interventions - of which Remimazolam is the first listed.

NCT07269808 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07269808 about?

NCT07269808 is a clinical study titled "Sedation During Endoscopy Using Remimazolam: Efficacy in a Novel Exploration". This study is a pragmatic, randomized controlled pilot trial comparing remimazolam with propofol for endoscopic procedures, designed to assess the feasibility and clinical outcomes associated with implementing a pragmatic randomized trial of sedation practices in the endoscopy setting.

What is the current status of trial NCT07269808?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2026-03-03. Estimated completion is 2026-06-01.

What conditions does trial NCT07269808 study?

This clinical trial studies the following conditions: Anesthesia, Sedation, Endoscopy.

What interventions are being tested in trial NCT07269808?

The interventions under investigation include: Remimazolam (DRUG), Propofol (DRUG).

Who is sponsoring clinical trial NCT07269808?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07269808 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anesthesia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.